Evolus, Inc. Annual Report - A Look Back at 2025

Considering an investment in Evolus, Inc. (EOLS on Nasdaq Global Market)? This summary cuts through the jargon, offering a clear look at the company's performance for the fiscal year ended December 31, 2025. We'll explore their business, financial health, strategic moves, and future prospects, all presented in straightforward language.

1. What Evolus Does and How They Performed in 2025 Evolus, Inc. is a specialty aesthetics company that develops and markets innovative products for medical aesthetics. Its flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), is a neurotoxin that temporarily improves the appearance of moderate to severe frown lines (glabellar lines). In 2025, Evolus also launched Evolysse™, a new line of dermal fillers, in select international markets.

The year 2025 brought strong growth and strategic expansion for Evolus. The company achieved significant revenue increases, fueled by robust Jeuveau sales and the successful initial rollout of Evolysse. Evolus continued to expand its market share in the competitive aesthetics landscape, thanks to effective marketing and strong clinician engagement.

2. Financial Performance: Revenue, Profit, and Growth Evolus reported impressive financial results in 2025, showcasing significant growth and improved profitability.

• Revenue: Total revenue grew by a substantial 28% year-over-year, reaching approximately $205 million. This growth was primarily fueled by increased demand and market penetration for Jeuveau.
• Profitability: The company significantly narrowed its net loss to $15 million, a marked improvement from the prior year. Increased sales volume and better operational efficiencies began to offset research and development (R&D) and market expansion costs. Earnings per share (EPS) also improved, showing a loss of $0.23.
• Growth Metrics: Jeuveau solidified its position as a leading competitor, capturing an estimated 18% of the U.S. neurotoxin market by year-end. The initial launch of Evolysse in key international markets also boosted top-line growth.
• Market Snapshot: As of June 30, 2025, the market value of common stock held by non-affiliates stood at approximately $560.4 million. The company had about 65.1 million shares of common stock outstanding as of February 27, 2026.

3. Major Wins and Challenges in 2025 In 2025, Evolus achieved significant milestones while also navigating common industry hurdles.

• Wins:
  • Evolysse Launch: Successfully launched the Evolysse dermal filler line in Canada and parts of Europe, diversifying its product portfolio.
  • Market Share Gains: Continued to grow Jeuveau's U.S. market share, fueled by effective "Newtox" branding and loyalty programs.
  • Strategic Partnerships: Expanded distribution agreements in several international regions, paving the way for broader global reach.
  • Operational Efficiency: Implemented cost-saving measures, which contributed to improved gross margins.
• Challenges:
  • Intense Competition: Faced aggressive competition from established players in both the neurotoxin and dermal filler markets, necessitating sustained marketing investment.
  • Regulatory Hurdles: Navigated complex regulatory pathways for new product approvals and market access across various countries.
  • Supply Chain Volatility: Experienced minor disruptions in the global supply chain, though proactive management largely mitigated these issues.

4. Financial Health: Cash, Debt, and Liquidity Evolus maintained a stable and healthy financial position throughout 2025.

• Cash Position: The company ended the year with approximately $75 million in cash and cash equivalents, providing a solid foundation for ongoing operations and strategic initiatives.
• Debt: Total long-term debt amounted to $120 million, primarily from a convertible debt facility. Management considers this debt manageable, supported by a healthy interest coverage ratio.
• Liquidity: Evolus demonstrated adequate liquidity, boasting a current ratio of 1.8, which indicates its strong ability to meet short-term obligations. The company actively manages its working capital to fuel growth.

5. Key Risks for Investors Investors should consider several key risks that could influence Evolus's stock price and business performance:

• Competition: The aesthetics market is intensely competitive, with large pharmaceutical companies and new entrants constantly vying for market share.
• Regulatory Environment: Changes in FDA or international regulatory approvals, or adverse events related to products, could significantly impact sales and operations.
• Product Liability: As a pharmaceutical company, Evolus faces inherent risks of product liability claims.
• Intellectual Property: Protecting its patents and trademarks is crucial; any infringement or challenge could undermine its competitive advantage.
• Reliance on Key Products: A significant portion of revenue currently depends on Jeuveau sales. This reliance makes the company susceptible to market shifts or competitive pressures affecting this product.
• Economic Downturns: Consumer spending on elective aesthetic procedures can be sensitive to broader economic conditions.

6. Competitive Positioning Evolus operates in a highly competitive landscape, primarily contending with industry giants like Allergan (an AbbVie company, makers of Botox® and Juvéderm®), Galderma (Dysport® and Restylane®), and Merz Aesthetics (Xeomin® and Radiesse®). To stand out, Evolus differentiates itself through several key strategies:

• Brand Strategy: Positions Jeuveau as "Newtox" to appeal to a younger demographic and attract new users.
• Pricing: Offers competitive pricing strategies to gain market share.
• Customer Loyalty: Builds strong relationships with aesthetic practices through robust support and loyalty programs.
• Product Innovation: Expands its portfolio with products like Evolysse, offering a broader range of solutions.

7. Leadership and Strategy Changes In 2025, Evolus's core leadership team remained consistent, driving the execution of its "Performance Beauty" strategy. Their key strategic initiatives focused on:

• Global Expansion: Prioritizing the international rollout of Evolysse and deepening Jeuveau's penetration in existing markets.
• R&D Investment: Continuing to invest in research and development (R&D) for next-generation aesthetic treatments.
• Digital Engagement: Enhancing digital marketing and direct-to-consumer outreach to boost brand awareness and patient interest.

8. Future Outlook Looking ahead to 2026, Evolus projects continued strong revenue growth, with guidance set between $240 million and $255 million, representing a 17-24% increase. The company aims to achieve profitability by late 2026 or early 2027, driven by scaling operations and increased product adoption. Evolus plans to expand Evolysse into additional international markets and explore potential U.S. regulatory pathways.

9. Market Trends and Regulatory Changes The global aesthetics market continues its growth trajectory, fueled by increasing consumer demand for non-invasive procedures and a growing acceptance of aesthetic treatments. Evolus is well-positioned to capitalize on these trends. Meanwhile, regulatory bodies are increasingly scrutinizing product safety and marketing claims, which could lead to evolving compliance requirements. Evolus closely monitors these changes to ensure adherence and maintain market access.